NO313180B1 - Bensökende alfapartikkel emitterende radiofarmasöytika - Google Patents
Bensökende alfapartikkel emitterende radiofarmasöytika Download PDFInfo
- Publication number
- NO313180B1 NO313180B1 NO20003457A NO20003457A NO313180B1 NO 313180 B1 NO313180 B1 NO 313180B1 NO 20003457 A NO20003457 A NO 20003457A NO 20003457 A NO20003457 A NO 20003457A NO 313180 B1 NO313180 B1 NO 313180B1
- Authority
- NO
- Norway
- Prior art keywords
- bone
- stated
- treatment
- actinium
- thorium
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title claims description 9
- 229940121896 radiopharmaceutical Drugs 0.000 title claims description 8
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims description 8
- 239000002245 particle Substances 0.000 title claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 51
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims abstract description 28
- 229910052776 Thorium Inorganic materials 0.000 claims abstract description 28
- 229910052767 actinium Inorganic materials 0.000 claims abstract description 27
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 210000004872 soft tissue Anatomy 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 14
- 208000018084 Bone neoplasm Diseases 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 25
- 230000003211 malignant effect Effects 0.000 claims description 15
- 239000002738 chelating agent Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229940125666 actinium-225 Drugs 0.000 claims description 11
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical group [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 claims description 10
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000013522 chelant Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008139 complexing agent Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 230000009920 chelation Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 230000005855 radiation Effects 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 5
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007987 MES buffer Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 5
- 229960005562 radium-223 Drugs 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- -1 strontium-89 compound Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 229940006509 strontium-89 Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- VGBPIHVLVSGJGR-UHFFFAOYSA-N thorium(IV) nitrate Inorganic materials [Th+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VGBPIHVLVSGJGR-UHFFFAOYSA-N 0.000 description 2
- OTWVIYXCRFLDJW-QMVMUTFZSA-N (1-hydroxy-1-phosphonooxyethyl) dihydrogen phosphate;rhenium-186 Chemical compound [186Re].OP(=O)(O)OC(O)(C)OP(O)(O)=O OTWVIYXCRFLDJW-QMVMUTFZSA-N 0.000 description 1
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001326189 Gyrodactylus prostae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 1
- KUVXYTRSDDFXMQ-UHFFFAOYSA-K [Ac+3].CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [Ac+3].CC([O-])=O.CC([O-])=O.CC([O-])=O KUVXYTRSDDFXMQ-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- QQINRWTZWGJFDB-OUBTZVSYSA-N actinium-228 Chemical compound [228Ac] QQINRWTZWGJFDB-OUBTZVSYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 210000000614 rib Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20003457A NO313180B1 (no) | 2000-07-04 | 2000-07-04 | Bensökende alfapartikkel emitterende radiofarmasöytika |
| JP2002511790A JP5219325B2 (ja) | 2000-07-04 | 2001-07-04 | 骨標的錯体 |
| PL366070A PL206209B1 (pl) | 2000-07-04 | 2001-07-04 | Zastosowanie emitującego cząstki alfa radionuklidu aktynu albo toru lub jego kompleksu skierowanego docelowo do kości, kompozycja radiofarmaceutyczna, skierowany docelowo do kości kompleks radionuklidu i jego zastosowanie w medycynie oraz zestaw do leczenia powierzchni kości albo nowotworów kośćca |
| CZ20030334A CZ299087B6 (cs) | 2000-07-04 | 2001-07-04 | Farmaceutický prostredek |
| US10/332,056 US7056275B2 (en) | 2000-07-04 | 2001-07-04 | Radiotherapy |
| EA200201258A EA004899B1 (ru) | 2000-07-04 | 2001-07-04 | Способ лучевой терапии |
| KR1020037000060A KR100892002B1 (ko) | 2000-07-04 | 2001-07-04 | 방사선 치료 방법 |
| AT01945519T ATE305313T1 (de) | 2000-07-04 | 2001-07-04 | Radiotherapy |
| AU2001267734A AU2001267734B2 (en) | 2000-07-04 | 2001-07-04 | Radiotherapy |
| SI200130456T SI1296722T1 (sl) | 2000-07-04 | 2001-07-04 | Radioterapija |
| DE60113683T DE60113683T2 (de) | 2000-07-04 | 2001-07-04 | Radiotherapy |
| CA002413736A CA2413736C (en) | 2000-07-04 | 2001-07-04 | Thorium or actinium radionuclides for endoradionuclide therapy |
| ES01945519T ES2250419T3 (es) | 2000-07-04 | 2001-07-04 | Radioterapia. |
| DK01945519T DK1296722T3 (da) | 2000-07-04 | 2001-07-04 | Radioterapi |
| PCT/GB2001/002996 WO2002005859A2 (en) | 2000-07-04 | 2001-07-04 | Radiotherapy |
| AU6773401A AU6773401A (en) | 2000-07-04 | 2001-07-04 | Method of radiotherapy |
| EP01945519A EP1296722B1 (de) | 2000-07-04 | 2001-07-04 | Radiotherapy |
| US11/337,385 US7335154B2 (en) | 2000-07-04 | 2006-01-23 | Radiotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20003457A NO313180B1 (no) | 2000-07-04 | 2000-07-04 | Bensökende alfapartikkel emitterende radiofarmasöytika |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20003457D0 NO20003457D0 (no) | 2000-07-04 |
| NO20003457L NO20003457L (no) | 2002-01-07 |
| NO313180B1 true NO313180B1 (no) | 2002-08-26 |
Family
ID=19911348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003457A NO313180B1 (no) | 2000-07-04 | 2000-07-04 | Bensökende alfapartikkel emitterende radiofarmasöytika |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7056275B2 (de) |
| EP (1) | EP1296722B1 (de) |
| JP (1) | JP5219325B2 (de) |
| KR (1) | KR100892002B1 (de) |
| AT (1) | ATE305313T1 (de) |
| AU (2) | AU2001267734B2 (de) |
| CA (1) | CA2413736C (de) |
| CZ (1) | CZ299087B6 (de) |
| DE (1) | DE60113683T2 (de) |
| DK (1) | DK1296722T3 (de) |
| EA (1) | EA004899B1 (de) |
| ES (1) | ES2250419T3 (de) |
| NO (1) | NO313180B1 (de) |
| PL (1) | PL206209B1 (de) |
| WO (1) | WO2002005859A2 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| CA2381123C (en) * | 2000-02-25 | 2011-10-04 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| US6670456B2 (en) * | 2001-02-28 | 2003-12-30 | Dow Global Technologies Inc. | Actinium-225 complexes and conjugates for targeted radiotherapy |
| ZA200507983B (en) * | 2003-04-15 | 2007-03-28 | Algetaas | Thorium-227 for use in radiotherapy of soft tissue disease |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| PL1735013T3 (pl) * | 2004-02-20 | 2012-07-31 | Algeta Asa | Cząstki hydroksyapatytu alfa- i beta-emitujące |
| LU91085B1 (en) * | 2004-06-25 | 2005-12-27 | European Community | Radionuclides for medical use. |
| EP1763372B1 (de) * | 2004-06-25 | 2016-11-30 | The European Union, represented by the European Commission | Radionuklide zur medizinischer anwendung |
| US7794691B2 (en) | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| GB0423565D0 (en) * | 2004-10-22 | 2004-11-24 | Algeta As | Formulation |
| US8709380B1 (en) * | 2006-02-07 | 2014-04-29 | Sirius Medicine, Llc | Targeting agents for enhancing radiation therapy |
| US8557601B2 (en) | 2006-07-10 | 2013-10-15 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| FR2913970B1 (fr) * | 2007-03-19 | 2009-06-12 | Cogema | Production de thorium 228 a partir d'un sel de thorium naturel |
| US20080249398A1 (en) * | 2007-04-09 | 2008-10-09 | Harder George Fred | Hybrid Source Containing Multi-Radionuclides for Use in Radiation Therapy |
| WO2011025790A1 (en) | 2009-08-24 | 2011-03-03 | Lumiphore, Inc. | Macrocyclic hopo chelators |
| JP2013515744A (ja) * | 2009-12-24 | 2013-05-09 | ルミフォア，インコーポレイテッド | 放射性医薬品錯体 |
| US9202602B2 (en) | 2010-02-10 | 2015-12-01 | Uchicago Argonne, Llc | Production of isotopes using high power proton beams |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
| GB201314718D0 (en) * | 2013-08-16 | 2013-10-02 | Algeta As | Quantification method |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| SG11201806548UA (en) | 2016-03-24 | 2018-08-30 | Bayer Pharma AG | Radio-pharmaceutical complexes |
| CR20180581A (es) | 2016-06-10 | 2019-02-11 | Bayer Pharma AG | Complejos radio-farmacéuticos |
| AU2018265386B2 (en) | 2017-05-11 | 2020-07-23 | Alpha Tau Medical Ltd. | Polymer coatings for brachytherapy devices |
| JP2021519126A (ja) | 2018-04-02 | 2021-08-10 | アルファ タウ メディカル リミテッド | 放射性核種の管理された放出 |
| FR3088769B1 (fr) * | 2018-11-15 | 2020-12-25 | Orano Med | Procede de preparation d'au moins un generateur a haute teneur en radium-228 |
| US20220152228A1 (en) * | 2019-03-01 | 2022-05-19 | Washington University | Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade |
| WO2021013978A1 (en) | 2019-07-25 | 2021-01-28 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| RU2767567C1 (ru) * | 2020-10-27 | 2022-03-17 | Станислав Анатольевич Дороватовский | Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата |
| US11857803B2 (en) | 2020-12-16 | 2024-01-02 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy with enhanced beta treatment |
| KR102545315B1 (ko) | 2021-01-05 | 2023-06-20 | 한국과학기술원 | 의료용 방사성 동위원소의 생산 방법 및 시스템 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2329147A (en) * | 1938-05-07 | 1943-09-07 | Rare Chemicals Inc | Stabilized metal sol and method of preparing same |
| US4560548A (en) * | 1984-04-10 | 1985-12-24 | The Dow Chemical Company | Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine |
| US4882142A (en) * | 1988-12-19 | 1989-11-21 | The Dow Chemical Company | Bone marrow suppressing agents |
| US5192526A (en) * | 1989-05-02 | 1993-03-09 | Mallinckrodt Medical, Inc. | Kit for preparation of rhenium therapeutic agents for bone cancer without purification |
| LU87684A1 (de) * | 1990-02-23 | 1991-10-08 | Euratom | Verfahren zur erzeugung von aktinium-225 und wismut-213 |
| US5902825A (en) * | 1997-01-07 | 1999-05-11 | Mitreoak, Ltd. | Composition and method for the palliation of pain associated with diseases of the bone and bone joints |
| FI104901B (fi) * | 1997-10-20 | 2000-04-28 | Leiras Oy | Uudet metyleenibisfosfonihappojohdannaiset |
| NO310544B1 (no) | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| JP2003501488A (ja) * | 1999-06-11 | 2003-01-14 | ネオルックス コーポレイション | 骨髄抑制のための高投与量放射性核種錯体 |
| NO314537B1 (no) | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| CA2381123C (en) | 2000-02-25 | 2011-10-04 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| US6548042B2 (en) * | 2000-08-07 | 2003-04-15 | Arstad Erik | Bis-phosphonate compounds |
| US6670456B2 (en) * | 2001-02-28 | 2003-12-30 | Dow Global Technologies Inc. | Actinium-225 complexes and conjugates for targeted radiotherapy |
| GB0213261D0 (en) | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
| US20030086868A1 (en) * | 2002-08-12 | 2003-05-08 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US20060228297A1 (en) | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
-
2000
- 2000-07-04 NO NO20003457A patent/NO313180B1/no not_active IP Right Cessation
-
2001
- 2001-07-04 KR KR1020037000060A patent/KR100892002B1/ko not_active IP Right Cessation
- 2001-07-04 ES ES01945519T patent/ES2250419T3/es not_active Expired - Lifetime
- 2001-07-04 DE DE60113683T patent/DE60113683T2/de not_active Expired - Lifetime
- 2001-07-04 AT AT01945519T patent/ATE305313T1/de active
- 2001-07-04 JP JP2002511790A patent/JP5219325B2/ja not_active Expired - Fee Related
- 2001-07-04 EP EP01945519A patent/EP1296722B1/de not_active Expired - Lifetime
- 2001-07-04 EA EA200201258A patent/EA004899B1/ru not_active IP Right Cessation
- 2001-07-04 CZ CZ20030334A patent/CZ299087B6/cs not_active IP Right Cessation
- 2001-07-04 US US10/332,056 patent/US7056275B2/en not_active Expired - Fee Related
- 2001-07-04 DK DK01945519T patent/DK1296722T3/da active
- 2001-07-04 CA CA002413736A patent/CA2413736C/en not_active Expired - Fee Related
- 2001-07-04 WO PCT/GB2001/002996 patent/WO2002005859A2/en active IP Right Grant
- 2001-07-04 AU AU2001267734A patent/AU2001267734B2/en not_active Ceased
- 2001-07-04 AU AU6773401A patent/AU6773401A/xx active Pending
- 2001-07-04 PL PL366070A patent/PL206209B1/pl unknown
-
2006
- 2006-01-23 US US11/337,385 patent/US7335154B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60113683D1 (en) | 2006-02-09 |
| WO2002005859A3 (en) | 2002-09-06 |
| US20060135842A1 (en) | 2006-06-22 |
| US7056275B2 (en) | 2006-06-06 |
| KR100892002B1 (ko) | 2009-04-07 |
| JP5219325B2 (ja) | 2013-06-26 |
| CA2413736A1 (en) | 2002-01-24 |
| AU6773401A (en) | 2002-01-30 |
| PL366070A1 (en) | 2005-01-24 |
| WO2002005859A2 (en) | 2002-01-24 |
| NO20003457L (no) | 2002-01-07 |
| AU2001267734B2 (en) | 2005-09-01 |
| CZ299087B6 (cs) | 2008-04-23 |
| KR20030029100A (ko) | 2003-04-11 |
| ATE305313T1 (de) | 2005-10-15 |
| DK1296722T3 (da) | 2006-02-13 |
| EA004899B1 (ru) | 2004-08-26 |
| NO20003457D0 (no) | 2000-07-04 |
| EP1296722A2 (de) | 2003-04-02 |
| ES2250419T3 (es) | 2006-04-16 |
| JP2004503331A (ja) | 2004-02-05 |
| US20030166989A1 (en) | 2003-09-04 |
| US7335154B2 (en) | 2008-02-26 |
| EP1296722B1 (de) | 2005-09-28 |
| CA2413736C (en) | 2009-08-18 |
| PL206209B1 (pl) | 2010-07-30 |
| DE60113683T2 (de) | 2006-07-06 |
| EA200201258A1 (ru) | 2003-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313180B1 (no) | Bensökende alfapartikkel emitterende radiofarmasöytika | |
| EP1140212B1 (de) | ANWENDUNG VON ZIELGERICHTETEM RADIUM 223 FüR PALLIATIVE UND THERAPEUTISCHE BEHANDLUNG VON KNOCHENKREBS | |
| Knapp Jr | Rhenium-188-A generator-derived radioisotope for cancer therapy | |
| AU2001267734A1 (en) | Radiotherapy | |
| Henriksen et al. | 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source | |
| JP2502601B2 (ja) | 放射性配位レニウム薬剤の単離および精製方法 | |
| Henriksen et al. | Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents | |
| Washiyama et al. | 227Th-EDTMP: A potential therapeutic agent for bone metastasis | |
| CA2926652C (en) | High purity therapeutic bone agents | |
| Zhernosekov | Radiochemical aspects of production and processing of radiometals for preparation of metalloradiopharmaceuticals | |
| NO317110B1 (no) | Nytt radiofarmasoytisk preparat | |
| Saichi et al. | 153-EDTMP for palliation of pain from osseous metastases: Preparation and biodistribution studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |